查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1603780

2030 年偏头痛治疗市场预测：按治疗类型、药物类别、给药途径、年龄层、严重程度、最终用户和地区进行的全球分析

Migraine Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Pharmacological Treatments and Non-Pharmacological Treatments), Drug Class, Route Of Administration, Age Group, Severity, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球偏头痛治疗市场规模将达到 34.6 亿美元，预计到 2030 年将达到 45.2 亿美元，预测期内复合年增长率为 6.2%。

偏头痛治疗是指旨在缓解偏头痛症状并预防未来发作的医疗策略。治疗选择包括急性治疗，如镇痛药（非类固醇抗发炎药、曲坦类药物和镇痛药）和预防性治疗，如β阻断剂、抗惊厥药和抗忧郁症。

据偏头痛研究基金会称，偏头痛是世界上第三大常见疾病，影响全球约 10 亿人。

偏头痛盛行率增加

随着越来越多的人经常或长期遭受偏头痛，对有效治疗方法的需求增加，从而导致市场不断扩大。压力、生活方式的改变和意识的提高等因素导致全球偏头痛患者的增加。不断增长的患者数量正在推动製药公司开发创新治疗方法，包括新药、设备和治疗方法。此外，人们对治疗选择的认识不断提高，导致医疗保健提供者提供专门的治疗，进一步增加了偏头痛急性和预防性治疗的市场需求。

偏头痛药物的副作用

偏头痛药物的副作用，如噁心、头晕、疲劳和潜在的心血管问题，可能会妨碍患者遵守治疗计画。曲坦类药物和某些预防药物可能会产生副作用，对某些人来说可能会超过其益处。由于需要替代治疗，此类副作用可能会导致处方治疗的停止、疗效下降以及医疗费用增加。这限制了某些药物的吸收并阻碍了偏头痛治疗市场。

虚拟咨询越来越受欢迎

远端医疗允许患者，特别是在偏远和服务欠缺地区的患者，无需亲自前往医疗机构即可咨询医疗保健专业人员。这对于需要定期后续观察、药物调整和治疗计划指导的偏头痛患者尤其有益。虚拟就诊可以及时诊断并开立 CGRP 抑制剂和其他偏头痛特异性治疗药物等药物处方，从而提高治疗依从性并减少医疗保健障碍。数位健康工具的整合进一步支援个人化医疗并推动市场扩张。

抗治疗性

当患者因遗传因素、药物过度使用或身体随着时间的推移对治疗的适应方式而对标准治疗没有反应时，就会出现偏头痛药物的抗治疗性。这种抗治疗性导致患者不满并增加对替代疗法的需求。它还增加了医疗保健成本，因为在发现治疗方法有效之前必须尝试多种治疗方法。此外，抗治疗性可能会阻止新患者接受治疗，从而影响市场成长和治疗依从性。

COVID-19 的影响

COVID-19 大流行对偏头痛治疗市场产生了重大影响，导致医疗服务中断、医疗程序延误以及前往治疗中心的机会有限。停工和压力增加增加了偏头痛的发生率，但许多患者在接受治疗时面临困难。远端医疗已成为重要的解决方案，可以透过虚拟咨询来开药。儘管面临这些挑战，市场对数位健康解决方案和家庭偏头痛管理方案的需求不断增长，从而塑造了疫情后的未来治疗趋势。

慢性偏头痛领域预计在预测期内规模最大

预计慢性偏头痛细分市场将在整个预测期内获得最大的市场占有率。慢性偏头痛治疗的重点是控制每月发生超过 15 天的频繁且持久的偏头痛发作。通常会采用 CGRP 抑制剂、肉毒桿菌注射、抗惊厥药物和β阻断剂预防性治疗来降低发作频率和严重程度。此外，早期疗育可以防止阵发性偏头痛发展为慢性偏头痛，这对患者俱有显着的健康和经济效益。

预计神经科在预测期内将经历最高的复合年增长率。

预计神经科在预测期内将经历最高的复合年增长率。神经科的偏头痛治疗涉及全面的方法，包括准确的诊断、个人化的治疗计划和持续的管理。神经科提供准确的诊断、最新的治疗方案以及对慢性和重症病例的专家管理。这种专门的治疗可以提高治疗效果，减少偏头痛频率，并提高患者的整体生活品质。

比最大的地区

由于意识的提高、获得医疗保健的机会的增加以及偏头痛相关疾病盛行率的增加，预计亚太地区将在预测期内创下最大的市场占有率。快速的都市化、高压力水平和生活方式的改变导致偏头痛患者增加。中国、印度和日本等国家对急性和预防性治疗（包括药物、治疗和设备）的需求不断增加。该市场得到政府措施和全部区域医疗基础设施改善的进一步支持。

复合年增长率最高的地区：

由于认知度高、医疗基础设施先进以及偏头痛盛行率不断上升，预计北美在预测期内的复合年增长率最高。由于 CGRP 抑制剂、肉毒桿菌注射和数位疗法等创新治疗方法的出现，美国和加拿大的市场正在扩大。该市场也受益于远端医疗的普及和个人化医疗的增加。主要企业正在专注于新型治疗和预防解决方案，以满足该地区不断变化的需求。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球偏头痛治疗市场：依治疗类型

  • 药物治疗
    • 早期预防医学
    • 预防医学
    • 非处方药
  • 非药物治疗
    • 行为疗法
    • 针刺
    • 经颅磁刺激（TMS）
    • 深部脑部刺激（DBS）
    • 神经阻断
    • 放鬆技巧

第六章全球偏头痛治疗市场：依药物类别

  • 曲普坦
  • 麦角胺衍生物
  • 抑钙素基因相关胜肽 (CGRP) 抑制剂
  • 抗忧郁症和抗癫痫药
  • 肉毒桿菌毒素
  • β受体阻断剂
  • 钙离子通道阻断剂
  • 其他药物类别

第七章全球偏头痛治疗市场：依给药途径

  • 口服
  • 注射
  • 鼻内
  • 经皮的

第八章全球偏头痛治疗市场：依年龄组

  • 儿科的
  • 成人
  • 进阶的

第九章全球偏头痛治疗市场：依严重程度

  • 慢性偏头痛
  • 阵发性偏头痛

第10章全球偏头痛治疗市场：依最终用户分类

  • 全科医生
  • 神经科
  • 家庭护理设置
  • 疗养院
  • 其他最终用户

第十一章全球偏头痛治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十三章 公司概况

  • Amgen Inc.
  • Eli Lilly and Co.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Allergan
  • Sanofi SA
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories
  • Cipla Limited
  • Mylan NV
  • Satsuma Pharmaceuticals Inc.
  • Biohaven Pharmaceutical Holding Company
  • Lundbeck A/S
  • Atogepant
  • Zosano Pharma Corporation
  • Kalydor
Product Code: SMRC27802

According to Stratistics MRC, the Global Migraine Treatment Market is accounted for $3.46 billion in 2024 and is expected to reach $4.52 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Migraine treatment refers to medical strategies aimed at relieving the symptoms and preventing future attacks of migraine headaches, which are characterized by intense, recurring pain often accompanied by nausea, vomiting, and sensitivity to light and sound. Treatment options include acute treatments, such as pain relief medications (NSAIDs, triptans, or painkillers), and preventive treatments, like beta-blockers, anticonvulsants, or antidepressants.

According to the Migraine Research Foundation, migraine is the third most common disease in the world, affecting an estimated 1 billion people globally.

Market Dynamics:

Driver:

Rising prevalence of migraines

As more individuals experience frequent or chronic migraines, there is a greater demand for effective treatments, leading to market expansion. Factors such as stress, lifestyle changes, and increasing awareness contribute to the growing number of migraine sufferers globally. This increased patient population encourages pharmaceutical companies to develop innovative treatments, including new medications, devices, and therapies. Additionally, the rising awareness about treatment options prompts healthcare providers to offer specialized care, further fueling market demand for both acute and preventive migraine treatments.

Restraint:

Adverse effects of migraine drugs

Adverse effects of migraine drugs, such as nausea, dizziness, fatigue, and potential cardiovascular issues, can discourage patient adherence to treatment plans. Medications like triptans and certain preventive drugs may cause side effects that outweigh their benefits for some individuals. These adverse reactions can lead to discontinuation of prescribed treatments, reduced efficacy, and increased healthcare costs due to the need for alternative therapies. This hampers the migraine treatment market by limiting the widespread use of certain drugs.

Opportunity:

Rising popularity of virtual consultations

Telemedicine allows individuals, especially in remote or underserved areas, to consult with healthcare professionals without the need for in-person visits. This is particularly beneficial for migraine patients who require regular follow-ups, medication adjustments, and guidance on treatment plans. Virtual consultations enable timely diagnosis and prescription of medications, such as CGRP inhibitors or other migraine-specific treatments, thus enhancing treatment adherence and reducing healthcare barriers. The integration of digital health tools further supports personalized care, fueling market expansion.

Threat:

Treatment resistance

Treatment resistance in migraine drugs occurs when patients do not respond to standard therapies, which can be due to genetic factors, medication overuse, or the body's adaptation to treatments over time. This resistance leads to patient dissatisfaction and increased demand for alternative therapies. It also drives up healthcare costs, as patients may need to try multiple treatments before finding one that works. Additionally, treatment resistance may deter new patients from seeking care, impacting market growth and treatment adherence.

Covid-19 Impact

The covid-19 pandemic significantly impacted the migraine treatment market, with disruptions in healthcare services, delays in medical procedures, and limited access to treatment centers. Lockdowns and increased stress led to a rise in migraine occurrences, yet many patients faced difficulties in obtaining treatments. Telemedicine emerged as a key solution, allowing virtual consultations for prescribing medications. Despite these challenges, the market saw growth in demand for digital health solutions and at-home migraine management options, shaping future treatment trends post-pandemic.

The chronic migraine segment is expected to be the largest during the forecast period

The chronic migraine segment is predicted to secure the largest market share throughout the forecast period. In chronic migraine treatment, the focus is on managing frequent, long-lasting migraine attacks occurring at least 15 days per month. Preventive treatments, such as CGRP inhibitors, Botox injections, anticonvulsants, and beta-blockers, are commonly prescribed to reduce the frequency and severity of attacks. Additionally, early intervention can prevent the progression of episodic migraines to chronic forms, offering significant health and economic benefits for patients.

The neurologists segment is expected to have the highest CAGR during the forecast period

The neurologists segment is anticipated to witness the highest CAGR during the forecast period. Migraine treatment by neurologists involves a comprehensive approach, including accurate diagnosis, personalized treatment plans, and ongoing management. They provide precise diagnosis, access to the latest treatment options, and expert management of chronic or severe cases. This specialized care improves treatment efficacy, reduces migraine frequency, and enhances overall quality of life for patients.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness, rising healthcare access, and a growing prevalence of migraine-related conditions. Rapid urbanization, high stress levels, and changing lifestyles contribute to a rise in migraine cases. Countries like China, India, and Japan are seeing rising demand for both acute and preventive treatments, including medications, therapies, and devices. The market is further supported by government initiatives and improving healthcare infrastructure across the region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period driven by high awareness, advanced healthcare infrastructure, and increasing migraine prevalence. In the U.S. and Canada, the market is expanding due to the availability of innovative treatments, including CGRP inhibitors, botox injections, and digital therapeutics. The market also benefits from growing telemedicine adoption and access to personalized care. Key players are focusing on novel therapies and preventative solutions to meet the region's evolving needs.

Key players in the market

Some of the key players profiled in the Migraine Treatment Market include Amgen Inc., Eli Lilly and Co., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Allergan, Sanofi S.A., Merck & Co., Inc., Dr. Reddy's Laboratories, Cipla Limited, Mylan N.V., Satsuma Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Lundbeck A/S, Atogepant, Zosano Pharma Corporation and Kalydor.

Key Developments:

In November 2023, Dr. Reddy's Laboratories launched Nerivio, a state-of-the-art United States Food and Drug Administration (USFDA) approved wearable therapy device for drug-free management of migraine, in the domestic market. It is to be used within 60 minutes of onset of headache for acute treatment of migraine or every alternate day.

In March 2023, Pfizer announced that it has received FDA approval for Zavegepant, a CGRP receptor antagonist nasal spray, marking the first nasal spray in this category for acute migraine treatment. It offers a fast-acting solution, with studies showing significant improvements in pain relief within 2 hours of use.

Treatment Types Covered:

  • Pharmacological Treatments
  • Non-Pharmacological Treatments

Drug Classes Covered:

  • Triptans
  • Ergotamine Derivatives
  • Calcitonin Gene-Related Peptide (CGRP) Inhibitors
  • Anti-depressants & Anti-epileptic Drugs
  • Botulinum Toxin
  • Beta-blockers
  • Calcium Channel Blockers
  • Other Drug Classes

Route Of Administrations Covered:

  • Oral
  • Injection
  • Intranasal
  • Transdermal

Age Groups Covered:

  • Pediatric
  • Adult
  • Geriatric

Severities Covered:

  • Chronic Migraine
  • Episodic Migraine

End Users Covered:

  • General Practitioners
  • Neurologists
  • Homecare Settings
  • Nursing Homes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Migraine Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Pharmacological Treatments
    • 5.2.1 Abortive Medications
    • 5.2.2 Preventive Medications
    • 5.2.3 Over-the-counter Medications
  • 5.3 Non-Pharmacological Treatments
    • 5.3.1 Behavioral Therapy
    • 5.3.2 Acupuncture
    • 5.3.3 Transcranial Magnetic Stimulation (TMS)
    • 5.3.4 Deep Brain Stimulation (DBS)
    • 5.3.5 Nerve Blocks
    • 5.3.6 Relaxation Techniques

6 Global Migraine Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Triptans
  • 6.3 Ergotamine Derivatives
  • 6.4 Calcitonin Gene-Related Peptide (CGRP) Inhibitors
  • 6.5 Anti-depressants & Anti-epileptic Drugs
  • 6.6 Botulinum Toxin
  • 6.7 Beta-blockers
  • 6.8 Calcium Channel Blockers
  • 6.9 Other Drug Classes

7 Global Migraine Treatment Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injection
  • 7.4 Intranasal
  • 7.5 Transdermal

8 Global Migraine Treatment Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric
  • 8.3 Adult
  • 8.4 Geriatric

9 Global Migraine Treatment Market, By Severity

  • 9.1 Introduction
  • 9.2 Chronic Migraine
  • 9.3 Episodic Migraine

10 Global Migraine Treatment Market, By End User

  • 10.1 Introduction
  • 10.2 General Practitioners
  • 10.3 Neurologists
  • 10.4 Homecare Settings
  • 10.5 Nursing Homes
  • 10.6 Other End Users

11 Global Migraine Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Amgen Inc.
  • 13.2 Eli Lilly and Co.
  • 13.3 AbbVie Inc.
  • 13.4 Teva Pharmaceutical Industries Ltd.
  • 13.5 Novartis AG
  • 13.6 Pfizer Inc.
  • 13.7 Johnson & Johnson
  • 13.8 GlaxoSmithKline plc
  • 13.9 Allergan
  • 13.10 Sanofi S.A.
  • 13.11 Merck & Co., Inc.
  • 13.12 Dr. Reddy's Laboratories
  • 13.13 Cipla Limited
  • 13.14 Mylan N.V.
  • 13.15 Satsuma Pharmaceuticals Inc.
  • 13.16 Biohaven Pharmaceutical Holding Company
  • 13.17 Lundbeck A/S
  • 13.18 Atogepant
  • 13.19 Zosano Pharma Corporation
  • 13.20 Kalydor

List of Tables

  • Table 1 Global Migraine Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Migraine Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 3 Global Migraine Treatment Market Outlook, By Pharmacological Treatments (2022-2030) ($MN)
  • Table 4 Global Migraine Treatment Market Outlook, By Abortive Medications (2022-2030) ($MN)
  • Table 5 Global Migraine Treatment Market Outlook, By Preventive Medications (2022-2030) ($MN)
  • Table 6 Global Migraine Treatment Market Outlook, By Over-the-counter Medications (2022-2030) ($MN)
  • Table 7 Global Migraine Treatment Market Outlook, By Non-Pharmacological Treatments (2022-2030) ($MN)
  • Table 8 Global Migraine Treatment Market Outlook, By Behavioral Therapy (2022-2030) ($MN)
  • Table 9 Global Migraine Treatment Market Outlook, By Acupuncture (2022-2030) ($MN)
  • Table 10 Global Migraine Treatment Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2022-2030) ($MN)
  • Table 11 Global Migraine Treatment Market Outlook, By Deep Brain Stimulation (DBS) (2022-2030) ($MN)
  • Table 12 Global Migraine Treatment Market Outlook, By Nerve Blocks (2022-2030) ($MN)
  • Table 13 Global Migraine Treatment Market Outlook, By Relaxation Techniques (2022-2030) ($MN)
  • Table 14 Global Migraine Treatment Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 15 Global Migraine Treatment Market Outlook, By Triptans (2022-2030) ($MN)
  • Table 16 Global Migraine Treatment Market Outlook, By Ergotamine Derivatives (2022-2030) ($MN)
  • Table 17 Global Migraine Treatment Market Outlook, By Calcitonin Gene-Related Peptide (CGRP) Inhibitors (2022-2030) ($MN)
  • Table 18 Global Migraine Treatment Market Outlook, By Anti-depressants & Anti-epileptic Drugs (2022-2030) ($MN)
  • Table 19 Global Migraine Treatment Market Outlook, By Botulinum Toxin (2022-2030) ($MN)
  • Table 20 Global Migraine Treatment Market Outlook, By Beta-blockers (2022-2030) ($MN)
  • Table 21 Global Migraine Treatment Market Outlook, By Calcium Channel Blockers (2022-2030) ($MN)
  • Table 22 Global Migraine Treatment Market Outlook, By Other Drug Classes (2022-2030) ($MN)
  • Table 23 Global Migraine Treatment Market Outlook, By Route Of Administration (2022-2030) ($MN)
  • Table 24 Global Migraine Treatment Market Outlook, By Oral (2022-2030) ($MN)
  • Table 25 Global Migraine Treatment Market Outlook, By Injection (2022-2030) ($MN)
  • Table 26 Global Migraine Treatment Market Outlook, By Intranasal (2022-2030) ($MN)
  • Table 27 Global Migraine Treatment Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 28 Global Migraine Treatment Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 29 Global Migraine Treatment Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 30 Global Migraine Treatment Market Outlook, By Adult (2022-2030) ($MN)
  • Table 31 Global Migraine Treatment Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 32 Global Migraine Treatment Market Outlook, By Severity (2022-2030) ($MN)
  • Table 33 Global Migraine Treatment Market Outlook, By Chronic Migraine (2022-2030) ($MN)
  • Table 34 Global Migraine Treatment Market Outlook, By Episodic Migraine (2022-2030) ($MN)
  • Table 35 Global Migraine Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 36 Global Migraine Treatment Market Outlook, By General Practitioners (2022-2030) ($MN)
  • Table 37 Global Migraine Treatment Market Outlook, By Neurologists (2022-2030) ($MN)
  • Table 38 Global Migraine Treatment Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 39 Global Migraine Treatment Market Outlook, By Nursing Homes (2022-2030) ($MN)
  • Table 40 Global Migraine Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.